Alzheimer's disease

Our laboratory has maintained close research collaboration in recent years with Elixiron Immunotherapeutics Inc., a company founded by alumni of our university. Recently, we jointly participated in the development of Enrupatinib, an oral immunomodulatory drug by invented by Elixiron Immunotherapeutics Inc. This drug has entered Phase II clinical trials for Alzheimer's disease at the leading neurological medical center, Taipei Veterans General Hospital. It holds promising potential to bring a breakthrough in the challenging field of new drug development for Alzheimer's disease.

The neuroimmune drug Enrupatinib was awarded funding twice, in 2020 and 2022, by the Part The Cloud-Gates Partnership program (a collaboration between the Alzheimer's Association and Bill Gates). Our team discovered that this drug has high safety and effectively inhibits the activation of microglia in the brain, reduces neuronal damage, and significantly improves neurodegenerative symptoms in mouse models of Alzheimer's disease.